{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:48:13Z","timestamp":1794271693140,"version":"4.9.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Natural killer (NK) cells are promising alternatives for the production of \u201coff-the-shelf\u201d CAR products, posing a lower risk of cytokine release syndrome (CRS) than CAR-T cells. We synthesized four single VHH-directed anti-BCMA CARs, incorporating various intracellular regions (2B4 <jats:italic>versus<\/jats:italic> CD28) and hinge domains (CD28 <jats:italic>versus<\/jats:italic> IgG1) and ectopically producing IL-15. NK cells derived from peripheral blood (PB) were expanded ex vivo by K562-mbIL21 feeder cells. Stable CAR transduction was obtained through lentiviral transduction with the BaEV-Rless pseudotyped lentiviral vector. BCMA-CD28-IL15 CAR-NK cells with ectopic expression of IL-15 exhibited superior cytotoxicity were compared to BCMA-CD28 CAR-NK cells lacking IL-15 and BCMA-hIgG1-IL15 CAR-NK cells with an IgG1 hinge domain. We further assessed the cytotoxic capabilities of BCMA-2B4-IL15 CAR-NK cells with 2B4 intracellular domain. The BCMA-CD28-IL15 CAR-NK cells revealed stronger cytotoxicity and higher cytokine secretion against BCMA<jats:sup>+<\/jats:sup> tumor cells than BCMA-2B4-IL15 CAR-NK cells in vitro. In the MM.1S-Luc mouse model, BCMA-CD28-IL15 CAR-NK inhibited the growth of tumor cells and prolonged mouse survival. These results show that the single VHH-directed BCMA CAR-NK cells exhibited remarkable specific killing ability, making them a potential candidate for immunotherapy in multiple myeloma treatment.<\/jats:p>","DOI":"10.1186\/s40164-023-00461-8","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T11:02:47Z","timestamp":1701082967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Single VHH-directed BCMA CAR-NK cells for multiple myeloma"],"prefix":"10.1186","volume":"12","author":[{"given":"Quan","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingling","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiumei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"461_CR1","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhou W, Yang J, Yang J, Wang W. Chimeric antigen receptor engineered natural killer cells for cancer therapy. Exp Hematol Oncol. 2023;12:70.","DOI":"10.1186\/s40164-023-00431-0"},{"key":"461_CR2","doi-asserted-by":"crossref","unstructured":"Mazinani M, Rahbarizadeh F. New cell sources for CAR-based immunotherapy. Biomarker Res. 2023;11:49.","DOI":"10.1186\/s40364-023-00482-9"},{"issue":"6428","key":"461_CR3","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446\u20138.","journal-title":"Nature"},{"issue":"10","key":"461_CR4","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41375-021-01269-3","volume":"35","author":"L Han","year":"2021","unstructured":"Han L, Zhang J-S, Zhou J, Zhou K-S, Xu B-L, Li L-L, et al. Single VHH-directed BCMA CAR-T cells cause remission of relapsed\/refractory Multiple Myeloma. Leukemia. 2021;35(10):3002\u20136.","journal-title":"Leukemia"},{"key":"461_CR5","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.3389\/fimmu.2019.02873","volume":"10","author":"ABL Colamartino","year":"2019","unstructured":"Colamartino ABL, Lemieux W, Bifsha P, Nicoletti S, Chakravarti N, Sanz J, et al. Efficient and robust NK-Cell Transduction with Baboon Envelope Pseudotyped Lentivector. Front Immunol. 2019;10:2873.","journal-title":"Front Immunol"},{"key":"461_CR6","doi-asserted-by":"crossref","unstructured":"Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J. NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol. 2021;14:7.","DOI":"10.1186\/s13045-020-01014-w"},{"key":"461_CR7","doi-asserted-by":"crossref","unstructured":"Wang X, Yang X, Yuan X, Wang W, Wang Y. Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential. Exp Hematol Oncol. 2022;11:85.","DOI":"10.1186\/s40164-022-00341-7"},{"issue":"6","key":"461_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"2","key":"461_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520\u201331.","journal-title":"Leukemia"},{"issue":"1","key":"461_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y, Klein Wolterink RGJ, Wang J, Bos GMJ, Germeraad WTV. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol. 2021;14(1):73.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"461_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-019-0732-7","volume":"12","author":"Y Xu","year":"2019","unstructured":"Xu Y, Liu Q, Zhong M, Wang Z, Chen Z, Zhang Y, et al. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies. J Hematol Oncol. 2019;12(1):49.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"461_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2018.06.002","volume":"23","author":"Y Li","year":"2018","unstructured":"Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived natural killer cells Engineered with chimeric Antigen receptors enhance anti-tumor activity. Cell Stem Cell. 2018;23(2):181\u201392. e5.","journal-title":"Cell Stem Cell"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00461-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-023-00461-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-023-00461-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T11:13:07Z","timestamp":1701083587000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-023-00461-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["461"],"URL":"https:\/\/doi.org\/10.1186\/s40164-023-00461-8","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All mouse experiments were performed and approved by the Institutional Animal Care and Use Committee (IACUC) of ANLING Laboratories (Shenzhen, China). Blood samples were collected from healthy donors with written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors critically reviewed and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"98"}}